TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+15.86%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$241M
AUM Growth
+$241M
(+7.4%)
Cap. Flow
-$5.24M
Cap. Flow
% of AUM
-2.17%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
13
New
1
Increased
1
Reduced
–
Closed
5
Top Buys
| 1 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
$3.31M |
| 2 |
Cyclacel Pharmaceuticals
CYCC
|
$2.16M |
Top Sells
| 1 |
Alibaba
BABA
|
$4.77M |
| 2 |
Nektar Therapeutics
NKTR
|
$3.7M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$1.22M |
| 4 |
Lipocine
LPCN
|
$790K |
| 5 |
Celldex Therapeutics
CLDX
|
$220K |
Sector Composition
| 1 | Healthcare | 90.86% |
| 2 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Heron Therapeutics
HRTX
$207M
| $107M | 44.29% | 6,197,198 | – | – |
|
|
LJPC
2
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $75.9M | 31.49% | 3,191,165 +139,035 | +5% | +$3.31M |
|
|
RXDX
3
DELISTED
Ignyta, Inc.
RXDX
| $25M | 10.36% | 3,972,800 | – | – |
|
4
BioMarin Pharmaceuticals
BMRN
$11.2B
| $8.35M | 3.46% | 90,215 | – | – |
|
|
5
Cyclacel Pharmaceuticals
CYCC
$18.4M
| $2.16M | 0.9% | +359,900 | New | +$2.16M |
|
|
ATYR
6
aTyr Pharma
ATYR
$527M
| $889K | 0.37% | 279,425 | – | – |
|
|
7
Alibaba
BABA
$322B
| – | – | -60,000 | Closed | -$4.77M |
|
|
8
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – | -430,000 | Closed | -$1.22M |
|
|
9
Celldex Therapeutics
CLDX
$1.47B
| – | – | -50,000 | Closed | -$220K |
|
|
10
Lipocine
LPCN
$15.8M
| – | – | -260,000 | Closed | -$790K |
|
|
11
Nektar Therapeutics
NKTR
$568M
| – | – | -260,000 | Closed | -$3.7M |
|